Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

By M. Ychou, V. Boige, Jean-Pierre Pignon, T. Conroy, O. Bouché, G. Lebreton, M. Ducourtieux, L. Bedenne, J. Fabre, B. Saint‐Aubert and 3 more. Journal of Clinical Oncology, 2011

1,827 citations recorded by the source corpus.

Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/394cac03d5bd07460d956c034901d5c2e342d7e8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Maciejewski
2. Robert Sitarz
3. Małgorzata Skierucha
4. J. Offerhaus
5. D. Cunningham
6. J. Mielko
7. W. Polkowski

Citations in the corpus

• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, result): “A subsequent French trial has reported similar results with the use of a 28-day regimen of perioperative cisplatin and 5-FU [34].”
• Gastric cancer: epidemiology, prevention, classification, and treatment (2018, background): “The results of perioperative chemotherapy in patients with GC and gastro-esophageal junction are promising.(91,93) A statistically significant improvement of overall survival and progression-free survival has been observed in 36% of patients with perioperative chemotherapy compared with 23% after th”
• Preoperative chemoradiotherapy for esophageal or junctional cancer. (2012, neutral): “Squamous-cell carcinoma 41 (23) 43 (23)”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “95) A [152]”